Upstate Active Clinical Trials
Study Title:INCB 18424-269 (COG AALL1521), A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2 Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia
What is the purpose of the study?This research study will find out if the study drug, ruxolitinib, in combination with standard HR B-ALL treatment is safe and effective in children, adolescents, and young adults with HR B-ALL.
Upstate Institutional Review Board (IRB) Number:950255
Study/Protocol ID:COG AALL1521
Study Phase:Phase II
Patient Age Group:Children
Principal Investigator:Melanie A Comito
Who can I contact for more information?
Name: Karen B Bilynsky